Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by IVERIC bio, Inc. < Previous 1 2 Next > Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 05, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 02, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 24, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Astellas Enters Into Definitive Agreement to Acquire Iveric Bio April 30, 2023 From IVERIC Bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting April 23, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 04, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 02, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results March 01, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference February 28, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023 February 22, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy February 16, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 02, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 04, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors January 03, 2023 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy December 20, 2022 From Iveric bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 02, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock November 30, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Announces Proposed Offering of Common Stock November 30, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy November 17, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy November 03, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results November 03, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 02, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022 October 27, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 04, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting September 27, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio to Present at Upcoming Investor Conferences September 07, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy September 06, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 02, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference August 10, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022 August 03, 2022 From IVERIC bio, Inc. Via Business Wire Tickers ISEE < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.